Oct. 1 at 5:10 PM
$IMRX I dived deeply down to check the two gold-standards of Oncology Studies - Median Overall Survival (mOS) and Median Progression-Free Survival (mPFS) between
$MRUS 's Bizengri and Immuneering's Atebimetinib + mGnP. The Phase 2 data published in The New England Journal of Medicine shows that the mPFS for Bizengri was 6.8 months, and its mOS for non-small-cell lung cancer (NSCLC) was 14.9 months.
In sharp contrast, IMRX's recent Phase 2 data in 1L pancreatic cancer showed mPFS for Atebimetinib + mGnP is 9.6 months, and although mOS data is not matured enough yet, the predicted mOS will be at least 24-27 months, which largely beating Bizengri's data by light years.
On Dec 4, 2024, the FDA granted accelerated approval to Bizengri.
My point is as OS gets matured enough for mOS calculation (about 8-12 months away), IMRX can definitely apply for accelerated approval at that point at least get Atebi for passionate use as this is definitely going to save lives of pancreatic cancer patients.
